Peptide receptor radionuclide therapy for neuroendocrine tumours

from Listen to The Lancet Oncology · host The Lancet

Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.

Episode metadata supplied by the publisher feed · Published Sep 5, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Peptide receptor radionuclide therapy for neuroendocrine tumours

0:00 19:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 19 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on September 5, 2020.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!